Douglas Ward
Algemeen Directeur bij LUMOS DIAGNOSTICS HOLDINGS LIMITED
Vermogen: 15 423 $ op 30-04-2024
Actieve functies van Douglas Ward
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Directeur/Bestuurslid | 13-07-2023 | - |
| Algemeen Directeur | 21-06-2022 | - |
Loopbaan van Douglas Ward
Eerdere bekende functies van Douglas Ward
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Algemeen Directeur | 09-05-2016 | 21-04-2020 |
| HOLOGIC, INC. | Corporate Officer/Principal | - | - |
Opleiding van Douglas Ward
| Ohio Wesleyan University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Australië | 2 |
Operationeel
| Chief Executive Officer | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
| HOLOGIC, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
- Beurs
- Insiders
- Douglas Ward
- Ervaring
